Fifty-two patients (22 women and 30 men; mean age, 48.2 ± 1.9 years; range, 22–70) with type 1 (n = 35; 21 women, 14 men; mean age, 43.4 ± 2.1 years; range, 22–65) or type 2 (n = 17; 8 women, 9 men; mean age, 57.9 ± 2.6 years; range, 32–70) diabetes were recruited at the Department of Ophthalmology at the Helsinki University Eye and Ear Hospital, and participated voluntarily in the study. A group of 27 age-matched healthy subjects (mean age, 49.1 ± 2.2 years; range, 26–67; 19 female and 8 male) served as a control group. The study protocol was approved by the Ethical Review Committees of Helsinki University Eye and Ear Hospital and the University Miguel Hernandez, and followed the tenets of the Declaration of Helsinki and the legal European Union regulations. A medical history was obtained from all of the patients, including age, sex, time from DM diagnosis (15.1 ± 1.6 years; range, 0.5–38), type of diabetes (DM1 or DM2), time from the onset of retinopathy (1.3 ± 0.2 years; range, 0.5–6), type of diabetic retinopathy (proliferative diabetic retinopathy, n = 21, or nonproliferative diabetic retinopathy, n = 31), type of argon laser treatment received by the patient (none, n = 19; focal photocoagulation, n = 12; panretinal photocoagulation, n = 21). Before sensitivity testing, the ocular surface of each patient was examined by biomicroscopy. All corneas were characterized by the absence of clinical signs of keratopathy and/or epithelial defects and corneal opacities.